Bioleaders Corporation (142760) - Total Liabilities
Based on the latest financial reports, Bioleaders Corporation (142760) has total liabilities worth ₩19.34 Billion KRW (≈ $13.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Bioleaders Corporation to assess how effectively this company generates cash.
Bioleaders Corporation - Total Liabilities Trend (2015–2024)
This chart illustrates how Bioleaders Corporation's total liabilities have evolved over time, based on quarterly financial data. Check 142760 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Bioleaders Corporation Competitors by Total Liabilities
The table below lists competitors of Bioleaders Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Celulosa Argentina SA
BA:CELU
|
Argentina | AR$343.59 Billion |
|
Bluglass Ltd
AU:BLG
|
Australia | AU$9.69 Million |
|
Everest Metals Corporation Ltd
AU:EMC
|
Australia | AU$1.66 Million |
|
Wealth Minerals Ltd.
V:WML
|
Canada | CA$447.12K |
|
Minesto AB
ST:MINEST
|
Sweden | Skr45.57 Million |
|
Japan Gold Corp
V:JG
|
Canada | CA$486.71K |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
Korea | ₩109.22 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Bioleaders Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 142760 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioleaders Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioleaders Corporation (2015–2024)
The table below shows the annual total liabilities of Bioleaders Corporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩24.94 Billion ≈ $16.90 Million |
+87.86% |
| 2023-12-31 | ₩13.28 Billion ≈ $9.00 Million |
-89.52% |
| 2022-12-31 | ₩126.73 Billion ≈ $85.88 Million |
-11.83% |
| 2021-12-31 | ₩143.74 Billion ≈ $97.41 Million |
-10.22% |
| 2020-12-31 | ₩160.09 Billion ≈ $108.49 Million |
+28.80% |
| 2019-12-31 | ₩124.30 Billion ≈ $84.23 Million |
-4.24% |
| 2018-12-31 | ₩129.79 Billion ≈ $87.96 Million |
+5284.50% |
| 2017-12-31 | ₩2.41 Billion ≈ $1.63 Million |
-41.92% |
| 2016-12-31 | ₩4.15 Billion ≈ $2.81 Million |
+4.09% |
| 2015-12-31 | ₩3.99 Billion ≈ $2.70 Million |
-- |
About Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more